Ardian Completes $47 Million Financing Led by Medtronic to Develop Hypertension Treatment
March 24, 2009 - Ardian Inc said yesterday Medtronic Inc. has led a $47 million financing of the company to develop a new catheter-based medical device to treat hypertension.
Joining Medtronic are Ardian's three existing investors Advanced Technology Ventures, Morgenthaler Ventures and Split Rock Partners, as well as new investor Emergent Medical Partners.
Hypertension, which affects approximately one-third of the developed world's adult population, significantly increases the risk of heart attack, stroke, heart failure and chronic kidney disease. It is the single most common contributor to death worldwide. Only 35 percent of hypertensive patients are satisfactorily controlled with medication. A major contributor to the development and perpetuation of hypertension is hyper-activation of the sympathetic nervous system. Ardian said its Symplicity Catheter System disrupts the renal sympathetic nerves by means of a straightforward 40-minute procedure, thereby reducing sympathetic activation and hence blood pressure.
Professor Henry Krum of the Alfred Hospital/Monash University in Melbourne, Australia, will present the early clinical experience with Ardian’s Symplicity Catheter System at the upcoming American College of Cardiology’s Annual Meeting (ACC.09) in Orlando, FL. This presentation will be part of a late-breaking clinical trials session scheduled for 9:15 am, Monday, March 30.
For more information: www.ardian.com
More like this
- Medtronic Gains European Approval for Symplicity Spyral Multi-Electrode Renal Denervation Catheter
- Medtronic Launches Two Trials Evaluating Renal Denervation Across Multiple Conditions
- Symplicity Renal Denervation System Participates in FDA Concurrent Review for PMA, Medicare Coverage Determination
- The Development of Renal Denervation Therapy
- Symplicity Renal Denervation Trial Shows Significant Blood Pressure Reduction, No Renal Impairment